The UK and US have agreed to a significant bilateral deal that will preserve no duties on British drug shipments going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost spending on drugs through the public health system. This pledge secures that tariffs on these key products will remain at zero for a duration of the next three years.
This agreement is in response to recent threats to significantly raise duties on branded pharmaceutical products, with potential rates floated up to 100%.
"This arrangement with the United Kingdom reinforces the international landscape for innovative medicines and brings much-needed balance to U.S.–U.K. medicine commerce," a statement declared.
Trade Importance
Medicines are one of the UK's most significant goods shipped to the United States, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Export figures show that in the year prior to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement secures jobs, increases investment and facilitates the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Detailed British Pledges
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments topped 20%.
Recent Tensions
The deal follows a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by assertions that US customers were charged significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while substantial funding commitments have been pledged toward US facilities.
One official stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had decreased as a proportion of its total funding over the previous ten-year period.
